Long-term experience with GH replacement therapy: Efficacy and safety

European Journal of Endocrinology, Supplement

Volumn 148, Issue 2, 2003, Pages

  Monson, John P ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOMATOMEDIN C;

ARTHRALGIA; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE REMODELING; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; DAILY LIFE ACTIVITY; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EDEMA; EPIDEMIOLOGICAL DATA; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GROWTH HORMONE DEFICIENCY; HEADACHE; HEMOGLOBIN DETERMINATION; HORMONE SUBSTITUTION; HOSPITAL ADMISSION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOPHYSIS ADENOMA; HYPOPITUITARISM; INSULIN RESISTANCE; LONG TERM CARE; MIGRAINE; MORTALITY; MYALGIA; OBESITY; PAIN; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; RIGIDITY; SEX DIFFERENCE; SIDE EFFECT; TITRIMETRY; TREATMENT OUTCOME; TUMOR GROWTH; WELLBEING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BODY COMPOSITION; BONE DENSITY; CHOLESTEROL, LDL; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; MALE; MIDDLE AGED;

EID: 0038301176     PISSN: 08044635     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. Abs R, Bengtsson BA, Hernberg-Stahl E, Monson JP, Tauber JP, Wilton P et al. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clinical Endocrinology 1999 50 703-713.
2. Lamberts SW, De Herder WW & Van Der Lely AJ. Pituitary insufficiency. Lancet 1998 352 127-134.
3. Rosen T & Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990 336 285-288.
4. Bates AS, Van't Hoff W, Jones PJ & Clayton RN. The effect of hypopituitarism on life expectancy. Journal of Clinical Endocrinology and Metabolism 1996 81 1169-1172.
5. Bülow B, Hagmar L, Mikoczy Z, Nordstrom CH & Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clinical Endocrinology 1997 46 75-81.
6. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN. Bates AS et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001 357 425-431.
7. Ehrnborg C, Hakkaart-Van Roijen L, Jonsson B, Rutten FF, Bengtsson BA & Rosen T. Cost of illness in adult patients with hypopituitarism. PharmacoEconomics 2000 17 621-628.
8. Monson JP, Abs R, Bengtsson BA, Bennmarker H, Feldt-Rasmussen U, Hernberg-Stahl E et al. Growth hormone deficiency and replacement in elderly hypopituitary adults. KIMS Study Group and the KIMS International Board. Pharmacia and Upjohn International Metabolic Database. Clinical Endocrinology 2000 53 281-289.
9. American Association of Clinical Endocrinologists, AACE clinical practice guidelines for growth hormone use in adults and children. Endocrine Practice 1998 4 165-173.
10. Thorner MO, Bengtsson B-Å, Ho KKY, Albertsson-Wikland KM, Christiansen JS, Faglia G et al. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism 1998 83 379-381.
11. Carroll PV, Christ ER & Sonksen PH. Growth hormone replacement in adults with growth hormone deficiency: assessment of current knowledge. Trends in Endocrinology and Metabolism 2000 11 231-238.
12. Cuneo RC, Salomon F, McGauley GA & Sonksen PH. The growth hormone deficiency syndrome in adults. Clinical Endocrinology 1992 37 387-397.
13. Cuocolo A, Nicolai E, Colao A, Longobardi S, Cardei S, Fazio S et al. Improved left ventricular function after growth hormone replacement in patients with hypopituitarism: assessment with radionuclide angiography. European Journal of Nuclear Medicine 1996 23 390-394.
14. Colao A, Cuocolo A, Di Somma C, Cerbone G, Della Morte AM, Nicolai E et al. Impaired cardiac performance in elderly patients with growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism 1999 84 3950-3955.
15. Wuster C, Abs R, Bengtsson BA, Bennmarker H, Feldt-Rasmussen U, Hernberg-Stahl E et al. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. Journal of Bone and Mineral Research 2001 16 398-405.
16. Drake WM, Howell SJ, Monson JP & Shalet SM. Optimizing GH therapy in adults and children. Endocrine Reviews 2001 22 425-450.
17. Kaufman JM, Taelman P, Vermeulen A & Vandeweghe M. Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset. Journal of Clinical Endocrinology and Metabolism 1992 74 118-123.
18. McKenna SP, Doward LC, Alonso J, Kohlmann T, Niero M, Prieto L et al. The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Quality of Life Research 1999 8 373-383.
19. Hernberg-Stahl E, Luger A, Abs R, Bengtsson BA, Feldt-Rasmussen U, Wilton P et al. Healthcare consumption decreases in parallel with improvements in quality of life during GH replacement in hypopituitary adults with GH deficiency. Journal of Clinical Endocrinology and Metabolism 2001 86 5277-5281.
20. Drake WM, Coyte D, Camacho-Hubner C, Jivanji NM, Kaltsas G, Wood DF et al. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. Journal of Clinical Endocrinology and Metabolism 1998 83 3913-3919.
21. Attanasio AF, Bates PC, Ho KK, Webb SM, Ross RJ, Strasburger CJ et al. Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status - 3-year results from the HypoCCS Database. Journal of Clinical Endocrinology and Metabolism 2002 87 1600-1606.
22. Florakis D, Hung V, Kaltsas G, Coyte D, Jenkins PJ, Chew SL et al. Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study. Clinical Endocrinology 2000 53 453-459.
23. Law MR, Wald NJ, Wu T, Hackshaw A & Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. British Medical Journal 1994 308 363-366.
24. Drake WM, Rodriguez-Arnao J, Weaver JU, James IT, Coyte D, Spector TD et al. The influence of gender on the short- and long-term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: a 5-year study. Clinical Endocrinology 2001 54 525-532.
25. Gotherstrom G, Svensson J, Koranyi J, Alpsten M, Bosaeus I, Bengtsson B et al. A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. Journal of Clinical Endocrinology and Metabolism 2001 86 4657-4665.
26. Riedl M, Ludvik B, Pacini G, Clodi M, Kotzmann H, Wagner O et al. The increased insulin sensitivity in growth hormone-deficient adults is reduced by growth hormone replacement therapy. European Journal of Clinical Investigation 2000 30 771-778.
27. Frajese G, Drake WM, Loureiro RA, Evanson J, Coyte D, Wood DF et al. Hypothalamo-pituitary surveillance imaging in hypopituitary patients receiving long-term GH replacement therapy. Journal of Clinical Endocrinology and Metabolism 2001 86 5172-5175.
28. Bengtsson BA, Koppeschaar HP, Abs R, Bennmarker H, Hernberg-Stahl E, Westberg B et al. Growth hormone replacement therapy is not associated with any increase in mortality. KIMS Study Group. Journal of Clinical Endocrinology and Metabolism 1999 84 4291-4292.